Veru (VERU) Free Cash Flow (2010 - 2026)
Veru (VERU) posted quarterly Free Cash Flow of -$8.9 million for Q1 2026, down 14.35% year-over-year from -$10.4 million in Q1 2025, and down 43.3% quarter-over-quarter from -$6.2 million in Q4 2025.
Veru (VERU) Free Cash Flow (2010 - 2026) Analysis & Trends
Veru (VERU) has reported Free Cash Flow for 17 consecutive years, with -$8.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 14.35% year-over-year to -$8.9 million; the TTM figure through Mar 2026 stood at -$26.0 million (up 10.96% YoY), while the FY2025 annual figure was -$30.0 million, down 37.25% from the prior year.
- Free Cash Flow retreated to -$8.9 million in Q1 2026 per VERU's latest filing, from -$6.2 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$4.1 million in Q1 2022 and bottomed at -$34.8 million in Q4 2022.
- Historically, Free Cash Flow has averaged -$11.5 million across 5 years, with a median of -$7.8 million in 2025.
- Annual changes were most pronounced in 2022 — Free Cash Flow slumped 1944.06% — and 2023, when it soared 82.71%.
- Veru's Free Cash Flow stood at -$34.8 million in 2022, then soared by 82.71% to -$6.0 million in 2023, then slumped by 87.71% to -$11.3 million in 2024, then soared by 45.14% to -$6.2 million in 2025, then plunged by 43.3% to -$8.9 million in 2026.
- Business Quant data shows VERU's Free Cash Flow at -$8.9 million in Q1 2026, -$6.2 million in Q4 2025, and -$5.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | -5.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.50 Mn |
| Jun 30, 2026 | -5.50 Mn |
| Mar 31, 2026 | -8.88 Mn |
| Mar 31, 2026 | -8.88 Mn |
| Dec 31, 2025 | -6.20 Mn |
| Dec 31, 2025 | -6.20 Mn |
| Sep 30, 2025 | -5.45 Mn |
| Sep 30, 2025 | -5.45 Mn |
| Jun 30, 2025 | -5.48 Mn |
| Jun 30, 2025 | -5.48 Mn |
| Mar 31, 2025 | -7.77 Mn |
| Mar 31, 2025 | -7.77 Mn |
| Dec 31, 2024 | -11.30 Mn |
| Dec 31, 2024 | -11.30 Mn |
| Sep 30, 2024 | -4.45 Mn |
| Sep 30, 2024 | -4.45 Mn |
| Jun 30, 2024 | -5.70 Mn |
| Jun 30, 2024 | -5.70 Mn |
| Mar 31, 2024 | -5.69 Mn |
| Mar 31, 2024 | -5.69 Mn |